Douglas Adkins
Washington University School of Medicine · Washington Univerisity · Washington University School of Medicine, Division of Oncology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Douglas Adkins as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:58 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06702033 · The Minimalist Trial-2Washington University School of Medicine · recruiting · HPV-Related Oropharynx Squamous Cell Carcinoma · principal investigator
- Ph3NCT04966481 · Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 InhibitorWashington University School of Medicine · recruiting · HPV-unrelated Head and Neck Squamous Cell Carcinoma · principal investigator
- Ph2NCT04643379 · Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell CarcinomaWashington University School of Medicine · active not recruiting · Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma · principal investigator
- Ph1NCT04624113 · Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell CarcinomaWashington University School of Medicine · terminated · Head and Neck Squamous Cell Carcinoma · principal investigator
- Ph2NCT03621696 · Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: "The Minimalist Trial (MINT)"Washington University School of Medicine · completed · HPV Related Oropharyngeal Squamous Cell Carcinoma · principal investigator
- Ph2NCT02573493 · Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)Washington University School of Medicine · completed · Squamous Cell Carcinoma of the Head and Neck, Carcinoma, Squamous Cell of the Head and Neck, Cancer of Head and Neck · principal investigator
- Ph1/Ph2NCT02101034 · PD 0332991 and Cetuximab in Patients With Incurable SCCHNWashington University School of Medicine · completed · Carcinoma, Squamous Cell of Head and Neck · principal investigator
- Ph1NCT01921426 · A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & NeckGalera Therapeutics, Inc. · completed · Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Oropharynx · principal investigator
- Ph1NCT01716416 · Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)Washington University School of Medicine · completed · Squamous Cell Carcinoma of the Head and Neck · principal investigator
- Ph2NCT01566435 · Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck CancerWashington University School of Medicine · completed · Head and Neck Neoplasms · principal investigator
- Ph2NCT01553851 · GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell CancerWashington University School of Medicine · completed · Neoplasms, Oral, Mouth Neoplasms · principal investigator
- Ph2NCT00736944 · Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck CancerWashington University School of Medicine · completed · Squamous Cell Carcinoma of the Head and Neck · principal investigator
- Ph2NCT00671437 · Determine Tumor Response Using Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET)/Computed Tomography (CT) Before and After Cetuximab in Patients With Head and Neck CancerWashington University School of Medicine · completed · Carcinoma, Squamous Cell · principal investigator
- Ph2NCT00441467 · Safety and Efficacy Study of Glufosfamide in Previously Treated Advanced Soft Tissue SarcomaEleison Pharmaceuticals LLC. · completed · Soft Tissue Sarcoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:58 UTC. The ranking covers the 200 most relevant of 78 PubMed records, and a shared surname and initials can bring in a namesake. All 78 on PubMed
- 552 citationsRCR 18.3
- 466 citationsRCR 14.5
- Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).J Clin Oncol · 2018380 citationsRCR 13.7
- 365 citationsRCR 89.3
- Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.Clin Cancer Res · 2020346 citationsRCR 13.8
- Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.Lancet Diabetes Endocrinol · 2021307 citationsRCR 17.7
- 237 citationsRCR 12.3
- Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide.Blood · 2001186 citationsRCR 4.6
- Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.Lancet Oncol · 2013149 citationsRCR 4.2
- Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit.J Clin Oncol · 1994143 citationsRCR 4.7